How to Get Jardiance in Colorado: Telehealth, Prescriptions, and Pharmacy Access

What Is Jardiance and Why Colorado Providers Prescribe It

Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor approved by the FDA for type 2 diabetes (2014), heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023). Colorado prescribers reach for it because it is one of the few oral agents with mortality data across three distinct organ systems simultaneously.

The key EMPA-REG OUTCOME trial (N=7,020) showed that empagliflozin 10 mg or 25 mg reduced the risk of cardiovascular death by 38% versus placebo in adults with type 2 diabetes and established cardiovascular disease (hazard ratio 0.62 to 95% CI 0.49, 0.77, P<0.001) [1]. That trial ran over a median follow-up of 3.1 years and enrolled patients from 42 countries. Hospitalization for heart failure fell by 35% in the empagliflozin group [1].

The EMPEROR-Reduced trial (N=3,730) extended the benefit to patients with heart failure and ejection fraction of 40% or less, showing a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.75 to 95% CI 0.65, 0.86, P<0.001) [2]. EMPEROR-Preserved (N=5,988) then demonstrated a 21% reduction in the same composite endpoint in patients with ejection fraction above 40% (HR 0.79 to 95% CI 0.69, 0.90, P<0.001) [3].

For kidney disease, the EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in the risk of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) [4]. Based on these trials, the 2023 American Diabetes Association Standards of Care recommend empagliflozin in patients with type 2 diabetes and CKD regardless of baseline HbA1c [5].

The FDA label for empagliflozin is publicly available through the FDA's accessdata portal and specifies contraindications including eGFR <20 mL/min/1.73 m² for CKD and dialysis-dependent renal failure [6].

Who Can Prescribe Jardiance in Colorado

Any licensed Colorado prescriber with independent prescribing authority can write for empagliflozin. That includes MDs, DOs, nurse practitioners (NPs) with full practice authority, and physician assistants (PAs) practicing under a supervision agreement.

Colorado is a full practice authority state for NPs under Colorado Revised Statutes § 12-255-112, meaning a nurse practitioner does not need a physician co-signature to prescribe Schedule II through V or non-scheduled drugs including empagliflozin [7]. PAs may prescribe under a delegated prescriptive authority agreement with their supervising physician, which must be filed with the Colorado Medical Board.

Telehealth providers licensed in Colorado can prescribe empagliflozin after establishing a valid patient-provider relationship, which Colorado law defines as including a synchronous audio-video visit. A phone-only visit without video does not satisfy this standard for a new controlled substance, though empagliflozin itself is not controlled; the Colorado Department of Regulatory Agencies has confirmed that a telehealth visit for a non-controlled drug requires a good-faith examination, which may be conducted by video or in person [8].

Labs Required Before a Jardiance Prescription in Colorado

Prescribers in Colorado order a defined set of labs before initiating empagliflozin, both to confirm the indication and to check for contraindications. You should expect the following panel at minimum.

Serum creatinine and eGFR. The FDA label contraindicates empagliflozin when eGFR falls below 20 mL/min/1.73 m² [6]. Between eGFR 20 and 45 mL/min/1.73 m², the drug is used specifically for its renal protective effect but glycemic efficacy diminishes. Your prescriber needs a result within the past 90 days, or they will order one before writing the script.

Urine albumin-to-creatinine ratio (ACR). The EMPA-KIDNEY trial entry criterion was urine ACR at or above 200 mg/g, or ACR between 100 and 200 mg/g with eGFR below 60 [4]. For the CKD indication, ACR is diagnostic. Even for the heart failure indication, ACR helps rule out pre-existing nephrotic syndrome.

HbA1c. Required for the type 2 diabetes indication. ADA guidelines define diagnostic thresholds at HbA1c 6.5% or above [5]. For heart failure or CKD prescribing, HbA1c is still ordered to establish glycemic context and guide concomitant diabetes management.

Basic metabolic panel. Includes sodium, potassium, bicarbonate, and glucose. SGLT2 inhibitors carry a small risk of euglycemic diabetic ketoacidosis (DKA), and baseline bicarbonate below 18 mEq/L prompts re-evaluation before initiation [9].

Blood pressure. Not a lab, but documented at the visit. Empagliflozin produces a mild blood pressure reduction of approximately 3 to 5 mmHg systolic, and the prescriber needs a baseline to monitor for hypotension in patients already on antihypertensives [10].

Most Colorado telehealth platforms connect to major lab networks including LabCorp and Quest Diagnostics. A requisition is sent electronically; you visit a draw site, results return in 24 to 72 hours, and the prescriber reviews them before finalizing the prescription.

How to Get a Jardiance Prescription Through Colorado Telehealth

The telehealth pathway is the fastest route for most Colorado residents. Here is a step-by-step sequence based on current standard of care in the state.

1. Schedule a video visit with a Colorado-licensed telehealth provider. Several national platforms operating in Colorado include Teladoc, Sesame, and HealthRX. The visit typically lasts 20 to 30 minutes for a new patient.

2. Upload your medical records. Bring or electronically send recent labs (within 90 days), a list of current medications, and any prior cardiology or nephrology notes. Prior authorization paperwork moves faster when the prescriber has your full clinical picture at the visit.

3. Complete the video consultation. The provider reviews your indication (diabetes, heart failure, or CKD), checks contraindications, and discusses risks including genital mycotic infections, urinary tract infections, and the rare but serious risk of Fournier's gangrene [6].

4. Lab order if needed. If your labs are older than 90 days or missing, the prescriber sends a lab requisition to your preferred draw site the same day.

5. Prescription transmitted electronically. Once labs are reviewed, the prescription is sent to your pharmacy via Colorado's Prescription Drug Monitoring Program (PDMP)-integrated e-prescribing system. Most telehealth platforms transmit within 2 to 4 hours of lab review.

6. Pharmacy dispenses. Major retail chains (King Soopers, Walgreens, King Soopers Pharmacy, Costco Pharmacy in Colorado) and mail-order pharmacies fill empagliflozin. With a manufacturer coupon, out-of-pocket cost for commercially insured patients with the Jardiance Savings Card can be reduced to as low as $10 per month [6].

The total timeline from first video visit to medication in hand ranges from 24 hours (if current labs are on file) to 5 to 7 business days (if labs must be drawn and prior authorization is required).

Prior Authorization for Jardiance in Colorado

Most Colorado commercial plans and both Colorado Medicaid and CHP+ require prior authorization for empagliflozin. The requirements differ by indication.

Type 2 diabetes PA. Colorado commercial plans typically require documentation of HbA1c at or above 7.0%, a trial of metformin (or contraindication to metformin), and current prescriber attestation of cardiovascular risk or established ASCVD. The ADA 2023 Standards of Care state: "For patients with type 2 diabetes and established CVD or high cardiovascular risk, SGLT2 inhibitors with proven cardiovascular benefit are recommended" [5]. That quoted language from a named guideline document can be submitted verbatim in PA requests.

Heart failure PA. Insurers require an echocardiogram report confirming the diagnosis, a current NYHA functional class documentation, and a note confirming the patient is on maximally tolerated guideline-directed medical therapy (GDMT) including a beta-blocker and ACE inhibitor or ARB, where appropriate. The 2022 AHA/ACC/HFSA Guideline gives SGLT2 inhibitors a Class I recommendation for HFrEF and a Class IIa recommendation for HFpEF [11].

CKD PA. Requires eGFR documentation (between 20 and 45 mL/min/1.73 m² for the CKD indication), urine ACR above 200 mg/g, and confirmation the patient is already on a maximally tolerated dose of an ACE inhibitor or ARB unless contraindicated. KDIGO 2022 guidelines recommend empagliflozin in patients with CKD and eGFR at or above 20 mL/min/1.73 m² [12].

Colorado Medicaid specifics. As of 2025, Colorado's Medicaid program covers empagliflozin for the heart failure and CKD indications but does not cover it as a first-line agent for type 2 diabetes alone without prior cardiovascular disease documentation. The Health First Colorado preferred drug list places empagliflozin in a non-preferred tier requiring PA for diabetes-only indications [8].

PA approval typically takes 3 to 5 business days. Expedited or peer-to-peer review can compress that to 24 hours when the prescriber calls the plan's medical director line directly.

Transferring a Jardiance Prescription to Colorado

If you are relocating to Colorado from another state and already have an active empagliflozin prescription, Colorado pharmacy law permits transfers under specific conditions. A pharmacist at a Colorado-licensed pharmacy can accept a transfer of a non-controlled prescription from an out-of-state pharmacy as long as the original prescription has refills remaining and was issued by a licensed prescriber in good standing [13].

To transfer your prescription, call the receiving Colorado pharmacy directly with the name and phone number of your current pharmacy. The Colorado pharmacist initiates the transfer. You do not need to schedule a new prescriber visit unless the prescription has zero refills remaining or has expired (prescriptions for non-controlled drugs in Colorado expire 12 months from the date written) [13].

If your prescription is out of refills, you have two options. First, ask your former prescriber to send a new prescription electronically to your Colorado pharmacy, which is legal across state lines. Second, establish care with a Colorado provider through a telehealth or in-person visit and have a new prescription written. Given empagliflozin's chronic-use nature, most Colorado prescribers will write a 90-day supply with refills at the first visit once they have reviewed your chart.

503A Compounding Pharmacies and Empagliflozin in Colorado

Colorado has licensed 503A compounding pharmacies that may compound empagliflozin for patients with documented need. 503A pharmacies operate under USP <795> and USP <800> standards and may compound from bulk active pharmaceutical ingredients for individual patient prescriptions [14].

Compounded empagliflozin is not FDA-approved and has not been evaluated in the same large-scale outcomes trials as the brand-name product. Patients who pursue compounded empagliflozin should do so under the supervision of a prescriber who documents the medical rationale, such as an allergy to an inactive excipient in the commercial tablet or a documented need for a non-standard dose.

Colorado's Pharmacist and Pharmacy Technician Program, administered by DORA, maintains a list of currently licensed 503A facilities [8]. Before filling at a compounding pharmacy, confirm the facility's current licensure status on the DORA website and verify the pharmacy has an active DEA registration if any controlled substances are handled on-site.

The FDA's 2023 guidance on compounding distinguishes between 503A and 503B facilities; 503A pharmacies serve individual patients based on a specific prescription, while 503B outsourcing facilities may produce larger batches [14]. For empagliflozin, the relevant pathway for most Colorado patients is 503A, since compounded versions are patient-specific.

Costs, Coupons, and Insurance in Colorado

Brand-name Jardiance has a list price of approximately $650 per month without insurance as of mid-2025. With commercial insurance, copays vary from $10 to $150 per month depending on the plan's tier placement.

Boehringer Ingelheim's Jardiance Savings Card program reduces out-of-pocket costs to $10 per month for eligible commercially insured patients with no deductible cap. Patients on federal programs (Medicare, Medicaid, TRICARE) are ineligible for the savings card but may qualify for the manufacturer's patient assistance program, which provides the drug at no cost for patients below 400% of the federal poverty level [6].

The Medicare Part D coverage gap remains relevant for Colorado Medicare beneficiaries. Under the Inflation Reduction Act (IRA) provisions effective 2025, the out-of-pocket cap for Part D is $2,000 annually, which reduces catastrophic-phase costs for high-cost drugs like Jardiance [15].

GoodRx coupons for empagliflozin at Colorado pharmacies range from $420 to $580 per month depending on chain and dose (10 mg vs 25 mg), which is still a significant out-of-pocket burden. Generic empagliflozin is not yet available in the United States as of July 2025, as Boehringer Ingelheim's core patents do not expire until 2025 to 2027 in different jurisdictions; the FDA has received Abbreviated New Drug Applications (ANDAs) but no generics have been approved yet [6].

Monitoring After Starting Jardiance in Colorado

Once empagliflozin is initiated, Colorado prescribers follow a defined monitoring schedule aligned with ADA and KDIGO recommendations [5] [12].

At the 4-week mark, most providers check blood pressure, weight, and any symptoms of genital mycotic infection or urinary symptoms. Serum creatinine may transiently rise by 5 to 10% in the first two weeks, a hemodynamic effect that typically stabilizes. This acute eGFR dip does not require stopping the drug and is mechanistically distinct from worsening kidney disease [4].

At 3 months, HbA1c is rechecked for the diabetes indication. The EMPA-REG OUTCOME trial showed HbA1c reductions of approximately 0.54% with empagliflozin 10 mg and 0.60% with 25 mg versus placebo at 12 weeks [1]. For the CKD or heart failure patient without diabetes, the 3-month visit focuses on eGFR trajectory, weight, and blood pressure response.

At 6 months and annually thereafter, a full metabolic panel, urine ACR, HbA1c (if diabetic), and blood pressure are standard. Patients on concurrent diuretics need closer electrolyte monitoring because SGLT2 inhibition has an additive natriuretic effect, and hyponatremia is possible in volume-depleted patients [9].

The FDA label includes a boxed-adjacent warning about lower limb amputations seen in the CANVAS trial of canagliflozin, a related SGLT2 inhibitor; empagliflozin's EMPA-REG OUTCOME data did not show a statistically significant amputation signal, but providers counsel patients on foot care as a class precaution [6] [1].